thiazoles has been researched along with Parkinsonian Disorders in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (60.00) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amireddy, N; Kalivendi, SV; Puttapaka, SN; Ravuri, HG; Thonda, S; Vinnakota, RL | 1 |
| Emoto, N; Hirata, KI; Nakayama, K; Okano, M; Okita, Y; Onishi, H; Shinke, T; Shinkura, Y; Tamada, N; Tanaka, H; Yanaka, KI | 1 |
| Agrawal, S; Kumari, N; Kumari, R; Luthra, PM; Sharma, D | 1 |
| Evans, RM; Martin, HL; Mounsey, RB; Mustafa, S; Nelson, MC; Sathe, K; Teismann, P | 1 |
| Bimpisidis, Z; Cenci, MA; Iderberg, H; Rylander, D | 1 |
| Damre, MV; Das, NR; Gangwal, RP; Sangamwar, AT; Sharma, SS | 1 |
| Andersen, JK; Beal, F; Dutta, AK; Rajagopalan, S; Shah, M; Shurubor, Y; Voshavar, C; Xu, L | 1 |
| Baekelandt, V; Debyser, Z; Deleersnijder, A; Gerard, M; Macchi, F; Michiels, A; Munck, S; Pottel, H; Van den Haute, C | 1 |
| Hasegawa, M; Higuchi, M; Hisanaga, SI; Imura, S; Masuda-Suzukake, M; Ono, M; Shimozawa, A; Takahara, D; Tarutani, A; Yanai, K | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Bilici, N; Gören, B; Korfali, E; Mimbay, Z; Oğul, E; Zarifoğlu, M | 1 |
| Baralatei, FT; Lauterbach, EC | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N | 1 |
| Auguet, M; Chabrier, PE; Ferrandis, E; Grandoulier, AS; Marin, JG; Mautino, G; Rocher, MN; Spinnewyn, B | 1 |
| Collins, LE; Pennarola, A; Port, RG; Sager, TN; Salamone, JD; Sams, AG; Shahriari, M | 1 |
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Breidert, T; Callebert, J; Heneka, MT; Hirsch, EC; Landreth, G; Launay, JM | 1 |
| Cadet, JL; Cutler, RG; Duan, W; Greig, NH; Guo, Z; Ladenheim, B; Mattson, MP; Oyler, J; Yu, QS; Zhu, X | 1 |
| Schapira, AH | 1 |
| Koyama, T; Nakagawa, S | 1 |
| Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR | 1 |
| Bernauer, E; Finsterer, J | 1 |
| Konieczny, J; Ossowska, K; Pilc, A; Wolfarth, S | 1 |
| Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Bezard, E; Gerlach, I; Gross, CE; Jork, R; Moratalla, R | 1 |
| Kanzato, N; Murao, H; Nishihira, T; Takara, H | 1 |
| Cansel, N; Herken, H; Ozen, ME; Savas, HA; Yumru, M | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Ondo, W; Tan, EK | 1 |
| Carvey, PM; Chen, EY; Ling, ZD; Lipton, JW; Ma, SY; Robie, HC; Tong, CW; Vu, TQ | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Ferger, B; Teismann, P | 1 |
| Anderson, DW; Neavin, T; Schneider, JS; Smith, JA | 1 |
| Montastruc, JL; Rascol, O | 1 |
| Dallocchio, C; Mazzarello, P | 1 |
2 review(s) available for thiazoles and Parkinsonian Disorders
| Article | Year |
|---|---|
Dopamine agonists and neuroprotection in Parkinson's disease.
Topics: Animals; Antioxidants; Benzothiazoles; Disease Models, Animal; Dopamine Agonists; Environmental Exposure; Humans; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Thiazoles | 2002 |
[Extrapyramidal syndrome].
Topics: Acute Disease; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dystonia; Humans; Indoles; Isoindoles; Parkinsonian Disorders; Quetiapine Fumarate; Receptors, Muscarinic; Receptors, Serotonin; Risperidone; Serotonin Antagonists; Syndrome; Thiazoles | 2003 |
33 other study(ies) available for thiazoles and Parkinsonian Disorders
| Article | Year |
|---|---|
The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cell Line, Tumor; Cell Respiration; Drug Approval; Helminths; Humans; Male; Membrane Potential, Mitochondrial; Mice; Mitochondria; Neurons; Nitro Compounds; Parkinsonian Disorders; Rats; Reactive Oxygen Species; Thiazoles; United States; United States Food and Drug Administration | 2017 |
Reversible Parkinsonism and Multiple Cerebral Infarctions after Pulmonary Endarterectomy in a Patient with Antiphospholipid Syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Cerebral Infarction; Chronic Disease; Endarterectomy; Heparin; Humans; Hypertension, Pulmonary; Male; Parkinsonian Disorders; Postoperative Complications; Pyridines; Thiazoles; Treatment Outcome; Warfarin | 2018 |
Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H)-yl)urea) in 6-OHDA induced rodent model of hemiparkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Depression; Disease Models, Animal; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats, Wistar; Reactive Oxygen Species; Rotarod Performance Test; Thiazoles; Tyrosine 3-Monooxygenase; Urea | 2018 |
A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Count; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Female; Glial Fibrillary Acidic Protein; Humans; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuroprotective Agents; Parkinsonian Disorders; PPAR delta; Rats; Sulfones; Thiazoles; Thiophenes; Tyrosine 3-Monooxygenase | 2013 |
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Pyridines; Rats; Receptor, Metabotropic Glutamate 5; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Dopamine D1; Serotonin Receptor Agonists; Thiazoles | 2013 |
A PPAR-β/δ agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson's disease.
Topics: Animals; Blotting, Western; Brain; Cognition; Disease Models, Animal; DNA Fragmentation; In Situ Nick-End Labeling; Male; Maze Learning; Neurons; Neuroprotective Agents; Parkinsonian Disorders; PPAR delta; PPAR-beta; Rats; Rats, Sprague-Dawley; Thiazoles | 2014 |
The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease.
Topics: Animals; Apoptosis; Cell Death; Dopaminergic Neurons; Dose-Response Relationship, Drug; Indoles; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Rats; Reactive Oxygen Species; Receptors, Dopamine D2; Receptors, Dopamine D3; Thiazoles | 2014 |
High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease.
Topics: alpha-Synuclein; Apoptosis; Benzothiazoles; Blotting, Western; Cell Count; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Genetic Vectors; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Indoles; Lentivirus; Microscopy, Fluorescence; Oxidative Stress; Parkinsonian Disorders; Protein Aggregation, Pathological; Protein Multimerization; Software; Thiazoles | 2016 |
Propagation of pathological α-synuclein in marmoset brain.
Topics: alpha-Synuclein; Animals; Benzothiazoles; Brain; Callithrix; Female; Immunohistochemistry; Lewy Bodies; Microglia; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Aggregation, Pathological; Recombinant Proteins; Sequence Homology, Amino Acid; Thiazoles; Tyrosine 3-Monooxygenase | 2017 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson model.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apomorphine; Aspirin; Behavior, Animal; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Immunohistochemistry; Meloxicam; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sympatholytics; Thiazines; Thiazoles | 2009 |
Switching to duloxetine remits ziprasidone - associated urinary incontinence and improves neuropsychiatric behavior in dementia: possible relationship of incontinence to 5HT2 receptor blockade.
Topics: Aged, 80 and over; Alzheimer Disease; Dementia, Vascular; Duloxetine Hydrochloride; Humans; Male; Parkinsonian Disorders; Piperazines; Receptors, Serotonin, 5-HT2; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Thiazoles; Thiophenes; Urinary Incontinence | 2009 |
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinsonian Disorders; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome | 2010 |
BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Area Under Curve; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles | 2011 |
The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Choice Behavior; Depression; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Haloperidol; Male; Molecular Targeted Therapy; Neurotoxicity Syndromes; Organophosphates; Parkinsonian Disorders; Pimozide; Prodrugs; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Thiazoles; Tremor | 2012 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Cell Count; Cell Survival; Corpus Striatum; Disease Models, Animal; Dopamine; Homovanillic Acid; Hypoglycemic Agents; Immunohistochemistry; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Neuroglia; Neurons; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Substantia Nigra; Thiazoles; Thiazolidinediones; Transcription Factors; Tyrosine 3-Monooxygenase | 2002 |
p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; Benzothiazoles; Dopamine; Dopamine Agents; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Thiazoles; Toluene; Tumor Suppressor Protein p53 | 2002 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.
Topics: Anti-Bacterial Agents; Antiparkinson Agents; Benzothiazoles; Brain; Chronic Disease; Dipeptides; Evoked Potentials, Visual; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Paromomycin; Pramipexole; Recovery of Function; Thiazoles; Treatment Outcome; Vision Disorders | 2005 |
MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
Topics: Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electromyography; Haloperidol; Male; Movement; Muscle, Skeletal; Parkinsonian Disorders; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Thiazoles; Time Factors | 2005 |
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Kynurenic Acid; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Mixed Function Oxygenases; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2005 |
5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease.
Topics: Animals; Benzopyrans; Brain; In Situ Hybridization; Macaca; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Thiazoles; Tyrosine 3-Monooxygenase | 2006 |
[Case of juvenile parkinsonism in pregnancy].
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Contraindications; Dopamine Agents; Dopamine Agonists; Ergolines; Family Planning Services; Female; Humans; Infant, Newborn; Levodopa; Parkinsonian Disorders; Pramipexole; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiazoles | 2006 |
Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
Topics: Adult; Antipsychotic Agents; Biperiden; Diagnosis, Differential; Diazepam; Drug Therapy, Combination; Humans; Infusions, Intravenous; Male; Neuroleptic Malignant Syndrome; Neurologic Examination; Parkinsonian Disorders; Piperazines; Schizophrenia; Thiazoles | 2007 |
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2008 |
Clinical characteristics of pramipexole-induced peripheral edema.
Topics: Adult; Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agonists; Edema; Female; Humans; Male; Middle Aged; Parkinsonian Disorders; Peripheral Nervous System Diseases; Pramipexole; Retrospective Studies; Severity of Illness Index; Thiazoles | 2000 |
Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine.
Topics: Animals; Benzothiazoles; Cell Count; Cell Death; Dopamine; Dopamine Agonists; Male; Neostriatum; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles | 2000 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Count; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Homovanillic Acid; Isoenzymes; Male; Meloxicam; Membrane Proteins; Mice; Mice, Inbred C57BL; Motor Activity; Neostriatum; Neuroprotective Agents; Parkinsonian Disorders; Prostaglandin-Endoperoxide Synthases; Substantia Nigra; Thiazines; Thiazoles; Tyrosine 3-Monooxygenase | 2001 |
Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Antiparkinson Agents; Benzothiazoles; Cell Survival; Dopamine; Dopamine Agents; Fluorescent Dyes; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neural Pathways; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Pramipexole; Stilbamidines; Substantia Nigra; Thiazoles; Tyrosine 3-Monooxygenase | 2001 |
Modafinil and pramipexole-associated somnolence.
Topics: Antiparkinson Agents; Benzhydryl Compounds; Benzothiazoles; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Dopamine Agonists; Humans; Modafinil; Parkinsonian Disorders; Pramipexole; Thiazoles; Treatment Outcome | 2001 |
A case of Parkinsonism due to lithium intoxication: treatment with Pramipexole.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Female; Humans; Lithium; Parkinsonian Disorders; Pramipexole; Severity of Illness Index; Thiazoles | 2002 |